The presence of SP-D could be associated with a favorable prognosis in lung cancer where it has been demonstrated to downregulate the EGF signaling, and unfavorable prognosis in non-pulmonary sites such as gastric, breast, and ovarian cancers. The gene discussed is SFTPD; the disease is ovarian cancer.